| Trial ID: | L2032 |
| Source ID: | NCT03417076
|
| Associated Drug: |
Bexagliflozin
|
| Title: |
Absolute Bioavailability Study With Bexagliflozin
|
| Acronym: |
|
| Status: |
WITHDRAWN
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Type 2 Diabetes Mellitus
|
| Interventions: |
DRUG: Bexagliflozin
|
| Outcome Measures: |
Primary: absolute bioavailability (Fp.o.) of bexagliflozin tablets, oral to IV ratio of dose-normalized AUC0-inf (area under the plasma concentration time curve extrapolated to infinity), Up to 48 hours | Secondary: adverse events, adverse event as a measure of safety and tolerability of treatment, Up to 3 days
|
| Sponsor/Collaborators: |
Sponsor: Theracos
|
| Gender: |
MALE
|
| Age: |
ADULT
|
| Phases: |
PHASE1
|
| Enrollment: |
0
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT
|
| Start Date: |
2018-08-01
|
| Completion Date: |
2018-09-16
|
| Results First Posted: |
|
| Last Update Posted: |
2019-09-30
|
| Locations: |
Clinical Research Site, Madison, Wisconsin, 53704, United States
|
| URL: |
https://clinicaltrials.gov/show/NCT03417076
|
